Global X Artificial Intelligence & Technology ETF vs Eli Lilly And Co — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $63.84, while Eli Lilly And Co trades at $1,222.8 (market cap $1.08T). The key difference: Eli Lilly And Co pays a 0.57% dividend while Global X Artificial Intelligence & Technology ETF pays none. Which is the better fit depends on your goals.
| AIQ | LLY | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $1.24K |
52-Week Low | $43.88 | $639.43 |
Market Cap | — | $1.08T |
Enterprise Value | — | $1.13T |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
AIQ, the Global X Artificial Intelligence & Technology ETF, trades at $63.79, up 0.44% on the day, with a bullish technical signal driven by moving averages. The ETF has gained attention for outperforming broader indices, with recent news highlighting its 25% gain and positioning in the AI sector. Key resistance lies at $64, while support is near $63.
The outlook remains positive due to strong momentum in AI investments, but risks include sector volatility and high valuations. Analyst sentiment is generally optimistic, with the ETF seen as a diversified play on AI growth, though the absence of dividend income and fee considerations may weigh on long-term returns.
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Trailing returns across standard periods
Latest headlines on both assets
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →